Full-Time

Assoc. Regulatory CMC Director

Confirmed live in the last 24 hours

Neurocrine Biosciences

Neurocrine Biosciences

1,001-5,000 employees

Biotechnology
Healthcare

Compensation Overview

$170.4k - $246.8kAnnually

+ Annual Bonus + Equity Incentive Program

Senior, Expert

San Diego, CA, USA

Category
Risk & Compliance
Legal & Compliance

You match the following Neurocrine Biosciences's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s degree in life science and 10+ years of experience in regulatory affairs in the pharmaceutical/biotech industry. Individual must have prior project regulatory leadership experience with specific focus on the CMC aspects for small molecules, large molecules and/or cell/gene therapies, including detailed knowledge of FDA and EMA regulations and guidance for drug development, preparation and management of IND/CTA/MAA/NDA/BLA. Prior experience with preparation and preferably, negotiation to marketing approval in major markets is desirable. OR
  • Master's degree in life science and 8+ years of similar experience as noted above
  • Sound knowledge and experienced with biologics (peptides, monoclonal antibodies, or cell and gene therapy) development and knowledge of small molecule CMC development.
  • Familiarity with regulatory guidelines and regulations governing biologics and small molecule CMC topics including aseptic manufacturing and platform processing technology concepts for biologics.
  • Able to critically review regulatory scientific documents across all CMC areas for biologics and small molecule modalities, as assigned.
  • Regulatory expertise in project leadership, preferably negotiation with and conduct of meetings with the FDA and successful preparation and submission of IND/CTA/MAA/NDA/BLA with explicit CMC focus for biologics and/or small molecule modalities.
  • Ability to effectively interact and communicate with multiple functions across the organization, including executive management
  • Requires broad understanding of the processes, procedures and systems used to accomplish the team’s work and familiarity with the underlying concepts in other disciplines within the function
  • Applies in-depth understanding of how own discipline integrates within the function and understands contribution to Neurocrine's achievement of business objectives
  • Ability to work as part of and lead multiple teams
  • Good leadership, mentoring skills and abilities typically leads lower levels and/or indirect teams
  • Excellent computer skills
  • Excellent problem-solving, analytical thinking skills
  • Sees broader picture and longer-term impact on division/company
  • Ability to meet multiple deadlines across a variety of projects/programs, with a high degree of accuracy and efficiency
  • Excellent project management, strong project leadership skills
  • Excellent verbal and written communication skills
  • Strong attention to detail
  • Possess excellent interpersonal skills
Responsibilities
  • Responsible for the regulatory CMC strategy and execution for assigned commercial and development projects, including responsibility for significant contributions to IND/CTA preparation, maintenance and update activities, interaction with and preparation for key milestone meetings with regulatory agencies, e.g., FDA and EMA, with focus on the CMC aspects for scientific areas such as, biologics and/or small molecule modalities
  • Leads development of CMC regulatory plans to ensure optimal product development leading to the earliest possible clinical clearances and/or approvals by relevant regulatory authorities
  • Provides expertise on global regulatory CMC requirements for multiple scientific areas, such as, but not limited to: biologics modalities (peptides, monoclonal antibodies, cell and gene therapy) and/or small molecule program management and project teams
  • Provides expert advice to product development team within CMC areas on all regulatory issues for the development, planning, compilation and submission of IND/CTA/MAA/NDA/BLA
  • May lead interactions and negotiations with regulatory agencies during all stages of development and registration
  • Leads preparation of regulatory submissions (IND/CTA/MAA/NDA/BLA)
  • Creates, reviews and edits reports and regulatory submissions
  • Actively engages with stakeholder groups to help shape science based regulatory decision making for multiple scientific areas including; biologics and small molecule
  • May acts as regulatory CMC liaison within the company, with partner companies, and contract manufacturers (CMOs) or research organizations (CROs)
  • Other duties as assigned
Desired Qualifications
  • Prior experience with preparation and preferably, negotiation to marketing approval in major markets is desirable.
Neurocrine Biosciences

Neurocrine Biosciences

View

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

N/A

Headquarters

San Diego, California

Founded

1992

Simplify Jobs

Simplify's Take

What believers are saying

  • CRENESSITY launch positions Neurocrine as a leader in niche markets with high unmet needs.
  • $500 million share repurchase indicates strong financial health and growth confidence.
  • Collaboration with Nxera Pharma could lead to innovative treatments for schizophrenia and dementia.

What critics are saying

  • Increased competition in neuropsychiatric drugs may impact Neurocrine's market share.
  • Potential delays in osavampator's Phase 3 program could affect market entry timeline.
  • Dependence on CRENESSITY's success in the U.S. market poses sales and reputation risks.

What makes Neurocrine Biosciences unique

  • Neurocrine focuses on first-in-class treatments for rare disorders like CAH.
  • Strategic collaboration with Takeda enhances Neurocrine's psychiatric disorder portfolio.
  • Partnership with PANTHERx Rare ensures specialized support for CRENESSITY distribution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Parental Leave

Health Insurance

Dental Insurance

Vision Insurance

Paid Holidays

Company News

PR Newswire
Feb 21st, 2025
Neurocrine Biosciences Board Of Directors Authorizes $500 Million Share Repurchase Program

SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares, subject to market conditions. This new share repurchase authorization is in addition to the $300 million accelerated repurchase program that was announced in October 2024 and completed in early February 2025.William Rastetter, Chairman of the Board of Directors of Neurocrine Biosciences, said, "This authorization reflects our approach to capital allocation that balances driving sustained revenue growth through investing in our commercial products, INGREZZA and CRENESSITY, advancing our expanding R&D pipeline and returning capital to shareholders."Under the new authorization, repurchases may be made from time to time at management's discretion through a variety of methods, such as open-market transactions including pre-set trading plans, privately negotiated transactions, accelerated share repurchases, and other transactions in accordance with applicable securities laws.About Neurocrine BiosciencesNeurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life- changing treatments for patients with under-addressed neuropsychiatric, neurological, and neuroendocrine disorders. The company's diverse portfolio includes U.S

PR Newswire
Jan 27th, 2025
Neurocrine Biosciences Announces Amendment To Strategic Collaboration With Takeda To Develop And Commercialize Osavampator (Formerly Nbi-1065845/Tak-653)

- Neurocrine Obtains Exclusive Worldwide Development and Commercialization Rights Excluding Japan and Converts to Royalty-Bearing License for Osavampator- Takeda Reacquires Rights to Osavampator in JapanSAN DIEGO, Jan. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the amended agreement, Neurocrine will obtain exclusive rights for all indications to develop and commercialize osavampator, a potential first-in-class AMPA positive allosteric modulator in development for patients with inadequate response to treatment of major depressive disorder (MDD) in all territories worldwide except Japan, where Takeda will reacquire exclusive rights. Under the terms of the updated agreement, each company is responsible for development costs in their respective region, and both companies are eligible to receive royalty payments."This streamlined collaboration structure allows Neurocrine to focus on bringing this important medicine to patients as quickly as possible," said Kyle Gano, Ph.D., Chief Executive Officer at Neurocrine Biosciences. "With the recent successful completion of our End-of-Phase 2 meeting with FDA for osavampator, we look forward to beginning the Phase 3 program in the first half of this year.""With its long-standing expertise developing therapies for serious psychiatric disorders, Neurocrine is the ideal partner to develop osavampator," said Sarah Sheikh, M.Sc., B.M., B.Ch, MRCP, Head, Neuroscience Therapeutic Area Unit and Head, Global Development at Takeda

PR Newswire
Jan 21st, 2025
Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today In The Journal Of Clinical Endocrinology Metabolism

SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a classic congenital adrenal hyperplasia (CAH)-focused supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM), sponsored by the company. The supplement, titled "Challenges and Opportunities in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Throughout the Lifetime," contains eight review articles that provide a comprehensive look at the clinical, psychosocial, treatment-related and day-to-day challenges faced by individuals with classic CAH. JCEM is a leader in disseminating research that supports healthcare providers, patients and caregivers in advancing the understanding and management of various endocrinology conditions, such as CAH."Our understanding of the genetics, pathophysiology, and complications of CAH has exploded over the last 20 years," said Dr. Richard Auchus, M.D., Ph.D., Principal Investigator, Professor of Pharmacology and Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes at the University of Michigan

ForexTV
Jan 14th, 2025
Nxera Pharma Provides Update on Neurocrine's Progress with its Partnered Muscarinic Agonist Portfolio

Nxera and Neurocrine entered a collaboration and licensing agreement in 2021 to develop a portfolio of novel clinical and preclinical subtype-selective muscarinic M4, M1 and dual M1/M4 receptor agonists discovered by Nxera for the treatment of schizophrenia, dementia and other neuropsychiatric disorders.

PR Newswire
Jan 6th, 2025
Neurocrine Biosciences To Present At The 43Rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 43rd Annual J.P. Morgan Healthcare Conference at 8:15 a.m. Pacific Time on Monday January 13, 2025 in San Francisco. Kyle Gano, Chief Executive Officer, will present at the conference.The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com